Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 1-2, 2015, Pages 65-72

  Florczak, Elzbieta ^a   Tokarczyk, Bogdan ^b   Warchoł Celiñska, Ewa ^a   Szwench Pietrasz, Elzbieta ^a   Prejbisz, Aleksander ^a   Gosk, Maria ^a   Kabat, Marek ^a   Narkiewicz, Krzysztof ^c   Januszewicz, Andrzej ^a   Kała, Maria ^b  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b INSTITUTE OF FORENSIC RESEARCH   (Poland)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Adherence to treatment; Resistant hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BISOPROLOL; CARVEDILOL; CLONIDINE; DILTIAZEM; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LACIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; PERINDOPRIL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TELMISARTAN; BIOLOGICAL MARKER;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; HYPERTENSION; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOMARKERS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 84924331919     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2648     Document Type: Article

References (24)

1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159-2219.
2. Fagard RH. Resistant hypertension. Heart. 2012; 98: 254-261.
3. Dela Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 171-174.
4. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125: 1635-1642.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011; 57: 1076-1080.
6. Florczak E, Prejbisz A, Szwench-Pietrasz E, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013; 27: 678-685.
7. Szwench E, Florczak E, Prejbisz A, et al. [Resistant hypertension-progress in diagnosis and treatment]. Kardiol Pol. 2012; 70: 66-74.
8. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008; 117: 510-526.
9. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001; 19: 2063-2070.
10. Egan BM, Zhao Y, Axon RN, et al. Uncotrolled and apparent treatment resistant hypertension in the United States, 1998 to 2008. Circulation. 2011; 57: 1046-1058.
11. Jung O, Gechter JL, Wunder C, et al. Resitant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013; 31: 766-774.
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353: 487-497.
13. Hill MN, Miller NH, Degeest S, et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens. 2011; 5: 56-63.
14. Burnier M, Santschi V, Favrat B, et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl. 2003; 21: 37-42.
15. Ceral J, Habradova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum anyihyperten-sive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011; 34: 87-90.
16. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed anti-hypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336: 1114-1117.
17. Bunker J, Callister W, Chang C, et al. How common is true resistant hypertension? J Hum Hypertens. 2011; 25: 137-140.
18. Strauch B, Petrak O, Zelinka T, et al. Precise assessment of non-compliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013; 31: 2455-2461.
19. Tomaszewski M, White Ch, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high performance liquid chroma-tography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014; 100: 855-861.
20. Tokarczyk B, Kala M. Screening for and quantification of 20 hypoten-sive drugs in whole blood by liquid chromatography-tandem mass spectrom-etry. Toxichem Krimtech. 2010; 77: 217.
21. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011; 123: 1611-1621.
22. Grenard JL, Munjas BA, Adams JL, et al. Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med. 2011; 26: 1175-1182.
23. Tomasik T, Gryglewska B, Windak A, Grodzicki T. Hypertension in the elderly: how to treat patients in 2013? The essential recommendations of the Polish guidelines. Pol Arch Med Wewn. 2013; 123: 409-416.
24. Uges DRA. Therapeutic and toxic drug concentrations. www.tiaft.org. Members' area. 2004. Accessed August 2014.